Preclinical safety, pharmacokinetics, and pharmacodynamics of recombinant human interleukin-21 in cynomolgus macaques (macaca fascicularis)

International Journal of Toxicology

Volumn 31, Issue 4, 2012, Pages 303-316

  Waggie, Kimberly S ^a   Holdren, Matthew S ^a   Byrnes Blake, Kelly ^a,b   Pedersen, Susan ^a,c   Ponce, Rafael ^a,c   Hughes, Steven ^a,d   Miller, Dennis M ^a,e  

^a BRISTOL MYERS SQUIBB   (United States)

^b Northwest PK Solutions ^*  (United States)

^c AMGEN INC   (United States)

^d Dendreon   (United States)

^e CPTxBio LLC   (United States)

Author keywords

cynomolgus monkey; IL 21; pathology; pharmacokinetics; preclinical safety; toxicology

Indexed keywords

ALANINE DEHYDROGENASE; ALBUMIN; BILIRUBIN; FIBRINOGEN; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 6; LACTATE DEHYDROGENASE; RECOMBINANT INTERLEUKIN 21; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ALBUMIN BLOOD LEVEL; ANEMIA; ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CELL INFILTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; DRUG SAFETY; FEMALE; FIBRINOGEN BLOOD LEVEL; LIVER SINUSOID; MACACA FASCICULARIS; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; THROMBOCYTOPENIA;

ACUTE-PHASE REACTION; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ESCHERICHIA COLI; FEMALE; HALF-LIFE; HUMANS; INTERLEUKINS; MACACA FASCICULARIS; MALE; PHOSPHORYLATION; RECOMBINANT PROTEINS; STAT3 TRANSCRIPTION FACTOR;

EID: 84865040840     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581812449661     Document Type: Article

References (35)

1. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000 ; 408 (6808). 57-63
2. Parrish-Novak J, Foster DC, Holly RD, Clegg CH. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol. 2002 ; 72 (5). 856-863 (Pubitemid 35365159)
3. Davis ID, Skak K, Smyth MH, Kristjansen P, Miller DM, Sivakumar PV. Interleukin-21 signaling: functions in cancer and autoimmunity. Clin Cancer Res. 2007 ; 13 (23). 6926-6932 (Pubitemid 350276871)
4. Moroz A, Eppolito C, Li Q, Tao J, Clegg CH, Shrikant PA. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol.. 2004 ; 173 (2). 900-909 (Pubitemid 38924263)
5. Brady J, Hayakawa Y, Smyth MJ, Nutt SL. IL-21 induces the functional maturation of murine NK cells. J Immunol. 2004 ; 172 (4). 2048-2058 (Pubitemid 38182350)
6. Sondergaard H, Frederiksen KS, Thygesen P, et al. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ cells and inhibits the growth of syngeneic tumors. Cancer Immunol Immunother. 2007 ; 56 (9). 1417-1428 (Pubitemid 47024706)
7. Takaki R, Hayakawa Y, Nelson A, et al. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol. 2005 ; 175 (4). 2167-2173 (Pubitemid 41113822)
8. International Conference on Harmonisation. Guidance for Industry. S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals; 1997. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM074957.pdfaccessed 4 May 2012.
9. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park). 2009 ; 23 (6). 488-496
10. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press ; 1996 :
11. Thomas P. Nonclinical evaluation of therapeutic cytokines: immunotoxicologic issues. Toxicology. 2002 ; 174 (1). 27-35 (Pubitemid 34327824)
12. Herzyk DJ, Soos JM, Maier CC, et al. Immunopharmacology of recombinant human interleukin-18 in non-human primates. Cytokine. 2002 ; 20 (1). 38-48 (Pubitemid 35373731)
13. Herzyk DJ, Bugelski PJ, Hart TK, Wier PJ. Preclinical safety of recombinant human interleukin-18. Toxicol Pathol. 2003 ; 31 (5). 554-561 (Pubitemid 37151428)
14. Hurwitz N, Probst A, Zufferey G, et al. Fatal vascular leak syndrome with extensive hemorrhage, peripheral neuropathy and reactive erythrophagocytosis: an unusual complication of recombinant IL-3 therapy. Leuk Lymphoma. 1996 ; 20 (3-4). 337-340 (Pubitemid 126714890)
15. van Gils FC, Mulder AH, van den Bos C, Burger H, van Leen RW, Wagemaker G. Acute side effects of homologous interleukin-3 in rhesus monkeys. Am J Pathol. 1003 ; 143 (6). 1621-1633
16. Vial T, Descotes J. Clinical toxicity of interleukin-2. Drug Saf. 1992 ; 7 (6). 417-33
17. Bree AG, Schlerman FJ, Kaviani MD, Hastings RC, Hitz SL, Goldman SJ. Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates. Biochem Biophys Res Commun. 1994 ; 204 (3). 1150-1157 (Pubitemid 24367172)
18. Gollob JA, Veenstra KG, Mier JW, Atkins MB. Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. J Immunother. 2001 ; 24 (1). 91-98 (Pubitemid 32101971)
19. Atkins MB, Kappler K, Mier JW, Isaacs RE, Berkman EM. Interleukin-6-associated anemia: determination of the underlying mechanism. Blood. 1995 ; 86 (4). 1288-1291
20. Ozaki K, Spolski R, Ettinger R, et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol. 2004 ; 173 (9). 5361-5371 (Pubitemid 39392119)
21. Breitfeld D, Ohl L, Kremmer E, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med. 2000 ; 192 (11). 1545-1551
22. Natkunam Y. The biology of the germinal center. Hematology Am Soc Hematol Educ Program. 2007 ; 2007 (1). 210-215
23. Pearse G. Normal structure, function, and histology of the thymus. Toxicol Pathol. 2006 ; 34 (5). 504-514 (Pubitemid 44652215)
24. De Meyts P, Urso B, Christoffersen CT, et al. Mechanism of insulin and IGF-1 receptor activation and signal transduction specificity. Receptor dimer cross-linking, bell-shaped curves, and sustained versus transient signaling. Ann N Y Acad Sci. 1995 ; 766: 388-401 (Pubitemid 26169119)
25. Boon L, Laman JD, Ortiz-Buijsse A, et al. Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys. Toxicology. 2002 ; 174 (1). 53-65 (Pubitemid 34327827)
26. Zwickl CM, Hughes BL, Piroozi KS, Smith HW, Wierda D. Immunogenicity of tissue plasminogen activators in rhesus monkeys: antibody formation and effects on blood level and enzymatic activity. Fundam Appl Toxicol. 1996 ; 30 (2). 243-254
27. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr Pharm Biotechnol. 2002 ; 3 (4). 349-360 (Pubitemid 35364009)
28. Anderson TD, Hayes TJ, Powers GD, Gately MK, Tudor R, Rushton A. Comparative toxicity and pathology associated with administration of recombinant IL-2 to animals. Int Rev Exp Pathol. 1993 ; 34 (pt A). 57-77
29. Harada Y, Yahara I. Pathogenesis of toxicity with human-derived interleukin-2 in experimental animals. Int Rev Exp Pathol. 1993 ; 34 (pt A). 37-55
30. Baluna R, Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology. 1997 ; 37 (2-3). 117-132 (Pubitemid 27471029)
31. Thompson JA, Curti BD, Redman BG, et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol. 2008 ; 26 (12). 2034-2039
32. Davis ID, Brady B, Kefford RF, et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a Phase IIa trial. Clin Cancer Res. 2009 ; 15 (6). 2123-2129
33. Davis ID, Skrumsanger BK, Cebon J, et al. An open-label, two-arm, Phase 1 trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res.. 2007 ; 13 (12). 3630-3636 (Pubitemid 46955126)
34. Cray C, Zaias J, Altman NH. Acute phase response in animals: a review. Comp Med. 2009 ; 59 (6). 517-526
35. Dodds MG, Fredericksen KS, Skak K, et al. Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins. Cancer Immunol Immunother. 2009 ; 58 (6). 843-854